<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02695745</url>
  </required_header>
  <id_info>
    <org_study_id>VND1004</org_study_id>
    <secondary_id>2011-002399-18</secondary_id>
    <nct_id>NCT02695745</nct_id>
  </id_info>
  <brief_title>Experimental Biomarker Study for Pain Thresholds</brief_title>
  <official_title>Randomized, Double Blind, Positive- Controlled, Three-way Cross-over Human Experimental Biomarker Study of V116517 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Purdue Pharma LP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the heat pain tolerance threshold (HPTolTr) in
      primary hyperalgesic skin after topical capsaicin application, and to assess heat pain and
      mechanical thresholds (eg, pressure pain, stimulus-response) following skin sensitization by
      UVB (ultraviolet B) irradiation and topical capsaicin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heat pain tolerance threshold (HPTolTr) in primary hyperalgesic skin after topical capsaicin application</measure>
    <time_frame>3.5 hours post-dose</time_frame>
    <description>Mean temperature in degrees Celsius (°C) based on the difference (post-dose and pre-dose) of the differences between the capsaicin at the control arm and the treated arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heat Pain Threshold (HPTr)</measure>
    <time_frame>3.5 hours post-dose</time_frame>
    <description>Mean temperature in degrees Celsius (°C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heat Pain tolerance threshold (HPTolTr)</measure>
    <time_frame>Pre-dose and 3.5 hours post-dose</time_frame>
    <description>Mean temperature in degrees Celsius (°C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure Pain Threshold (PPTr)</measure>
    <time_frame>3.5 hours post-dose</time_frame>
    <description>Mean pressure kPA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure Pain tolerance threshold (PPTolTr)</measure>
    <time_frame>3.5 hours post-dose</time_frame>
    <description>Mean pressure kPA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral nociceptor activation using Laser Doppler flowmetry</measure>
    <time_frame>3.5 hours post-dose</time_frame>
    <description>Peripheral nociceptor activation will be assessed by monitoring cutaneous blood flow using Laser Doppler imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythema at the treated area using Erythema index</measure>
    <time_frame>3.5 hours post-dose</time_frame>
    <description>Erythema at the treated area will be assessed using colorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stimulus-response function to graded von Frey hair stimulation</measure>
    <time_frame>3.5 hours post-dose</time_frame>
    <description>The mean pain intensity of the stimulations on a '0-10' visual analog scale (VAS), where '0' indicates ''no pain&quot; and '10' indicates '' the most intense pain imaginable''</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary pin-prick hyperalgesic area</measure>
    <time_frame>3.5 hours post-dose</time_frame>
    <description>The area will be assessed using a 60 g weighted von Frey hair, and subjects are asked to report when the sensation changes to a &quot;different sensation&quot;, &quot;unpleasant&quot; or &quot;burning pain&quot; sensation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of change in body temperature</measure>
    <time_frame>Pre-dose and up to 72 hours post-dose</time_frame>
    <description>Oral temperature in degrees Celsius (˚C)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>V116517</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V116517 aqueous suspension; 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib capsules; 400 mg (2 capsules of 200 mg each)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V116517 aqueous suspension</intervention_name>
    <description>300 mg (approximately 100 mL) aqueous suspension taken orally x 1 dose</description>
    <arm_group_label>V116517</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib capsules</intervention_name>
    <description>400 mg (2 capsules of 200 mg each) taken orally x 1 dose</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>Celebrex®</other_name>
    <other_name>Celebra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose</description>
    <arm_group_label>V116517</arm_group_label>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capsaicin</intervention_name>
    <description>1% administered topically</description>
    <arm_group_label>V116517</arm_group_label>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:

          1. Signed informed consent obtained.

          2. Males aged 18 to 45, inclusive.

          3. Body weight ranging from 50 to 100 kg and BMI ranging from 18 to 32 (kg/m2),
             inclusive.

          4. Healthy and free of significant abnormal findings as determined by medical history,
             physical examination, clinical laboratory values, vital signs, and ECG.

        Exclusion Criteria include:

          1. Current or recent (within 5 years) history of drug or alcohol abuse.

          2. History or any current conditions that might interfere with drug absorption,
             distribution, metabolism or excretion.

          3. Any history of frequent nausea or emesis regardless of etiology.

          4. Any history of allergic-type reactions to sulfonamides, or any experience of asthma,
             urticarial, or other allergic-type reactions after taking aspirin or other NSAIDS.

          5. Subjects who do not develop erythema at the maximum dose of the UVB source (MED
             determination for UVB model) will be excluded from the study.

        Other protocol-specific inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CCBR A/S</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2016</study_first_submitted>
  <study_first_submitted_qc>February 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2016</study_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

